公开(公告)号：US20240325538A1

公开(公告)日：2024-10-03

申请号：US18254167

申请日：2021-11-25

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Zhou HE ,  Tiantian LI ,  Yongchao SHEN ,  Haibin CHEN ,  Chen HUANG ,  Fuhui XU

IPC: A61K39/00 ,  A61P35/00 ,  C12N5/0783

CPC classification number: A61K39/464499 ,  A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2309 ,  C12N2501/231 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/515 ,  C12N2501/52 ,  C12N2502/30

Abstract: A culture composition for expanding a TIL, containing IL-2, IL-7, IL-15, and an immune checkpoint antibody or an antigen-binding fragment thereof. The immune checkpoint antibody comprises any one or more of a PD-1 antibody, a CTLA-4 antibody, a LAG-3 antibody, a TIM-3 antibody, a TIGIT antibody, and a BTLA antibody. The present invention further relates to a TIL expanding culture medium, a method for preparing a TIL population, and a pharmaceutical composition. In the culture composition, cell proliferation and activity are ensured while greatly reducing the used amount of IL-2, and IL-2 treatment is removed after infusing the TILs obtained using the culture composition into a patient so as to reduce side effects; moreover, no feeder cells are used in an expansion process, exogenous pollution is reduced and the manufacturing process is simplified, the manufacturing costs reduced, and the manufacturing time shortened.

公开(公告)号：US20240216507A1

公开(公告)日：2024-07-04

申请号：US17907180

申请日：2021-03-22

Applicant: CHILDREN'S NATIONAL MEDICAL CENTER

Inventor： Catherine BOLLARD ,  Michael KELLER ,  Chris LAZARSKI ,  Allistair ABRAHAM ,  Patrick HANLEY ,  Conrad Russell Y. CRUZ

IPC: A61K39/00 ,  C12N5/0783

CPC classification number: A61K39/4611 ,  A61K39/464838 ,  C12N5/0636 ,  C12N2501/2304 ,  C12N2501/2307

Abstract: The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.

公开(公告)号：US12016881B2

公开(公告)日：2024-06-25

申请号：US17396792

申请日：2021-08-09

Applicant: NEW YORK UNIVERSITY

Inventor： Dafna Bar-Sagi ,  Jane Cullis ,  Craig Ramirez

IPC: A61K38/38 ,  A61K31/337 ,  A61K35/15 ,  A61K38/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61P35/00 ,  C07K14/52 ,  C07K14/53 ,  C07K14/54 ,  C07K14/76 ,  C07K14/765 ,  C12N5/0786

CPC classification number: A61K35/15 ,  A61K31/337 ,  A61K38/00 ,  A61K38/18 ,  A61K38/19 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2006 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/385 ,  A61P35/00 ,  C07K14/52 ,  C07K14/53 ,  C07K14/54 ,  C07K14/5406 ,  C07K14/5428 ,  C07K14/76 ,  C07K14/765 ,  C12N5/0645 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2333 ,  C12N2501/24 ,  C12N2501/25

Abstract: The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.

公开(公告)号：US11993788B2

公开(公告)日：2024-05-28

申请号：US16610534

申请日：2018-05-03

Applicant: Oxford University Innovation Limited

Inventor： Kathryn J. Wood ,  Sushma Shankar

IPC: C12N5/0781 ,  A61K35/17 ,  C07K16/28 ,  G01N33/50

CPC classification number: C12N5/0635 ,  A61K35/17 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2878 ,  C07K16/2887 ,  G01N33/5091 ,  C07K2317/31 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/231 ,  C12N2501/2321 ,  C12N2501/52 ,  C12N2501/599 ,  G01N2800/24 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56

Abstract: The present invention relates to an expanded population of human Breg cells having the phenotype CD19+CD73−CD71+CD25+TIM-1+ and methods for producing the cell population of the invention. The invention also relates to pharmaceutical compositions comprising the cell populations of the invention and their use in the treatment of immune-mediated disorders.

公开(公告)号：US11981923B2

公开(公告)日：2024-05-14

申请号：US17659624

申请日：2022-04-18

Applicant: Baylor College of Medicine

Inventor： Ann Marie Leen ,  Juan Fernando Vera Valdes ,  Cliona M. Rooney ,  Ulrike Gerdemann

IPC: C12N5/0783 ,  A61K39/12 ,  C07K14/025 ,  C07K14/03 ,  C07K14/11 ,  C07K14/135 ,  C12N7/00 ,  A61K39/00

CPC classification number: C12N5/0638 ,  A61K39/12 ,  C07K14/025 ,  C07K14/03 ,  C07K14/11 ,  C07K14/135 ,  C12N7/00 ,  A61K2039/5158 ,  A61K2039/55527 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/577 ,  A61K2039/70 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2710/16134 ,  C12N2710/16234 ,  Y02A50/30

Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.

公开(公告)号：US11976299B2

公开(公告)日：2024-05-07

申请号：US16334872

申请日：2017-09-18

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Gal Cafri ,  Paul F. Robbins ,  Jared J. Gartner ,  Steven A. Rosenberg

IPC: A61K35/15 ,  C12N5/0784

CPC classification number: C12N5/0639 ,  A61K35/15 ,  C12N2501/02 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/52 ,  C12N2501/999 ,  C12N2502/1114

Abstract: Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.

公开(公告)号：US11952586B2

公开(公告)日：2024-04-09

申请号：US16888213

申请日：2020-05-29

Applicant: Hoffmann-La Roche Inc.

Inventor： Sonja Offner ,  Friederike Jung

IPC: C12N5/00 ,  C12N5/0781

CPC classification number: C12N5/0635 ,  C12N2500/30 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2321 ,  C12N2501/25 ,  C12N2502/1107 ,  C12N2529/00

Abstract: Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.

公开(公告)号：US20240076616A1

公开(公告)日：2024-03-07

申请号：US18262268

申请日：2022-01-21

Applicant: Cytovac A/S

Inventor： Alexei Kirkin

IPC: C12N5/0783 ,  A61K35/17 ,  C12N5/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  C12N5/0018 ,  C12N2501/02 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2312 ,  C12N2501/25 ,  C12N2502/1121

Abstract: Provided is a method for preparation of a composition comprising activated human CD4+ and CD8+ lymphocytes. The method entails use of allogeneic mature dendritic cells as feeder cells added at an early stage in the induction of proliferation and activation of CD4+ and CD8+ T cells. Further provided is a method for treatment of lymphopenia related diseases by infusion of the cells obtained from the present process.

公开(公告)号：US20230405118A1

公开(公告)日：2023-12-21

申请号：US18251060

申请日：2021-10-29

Applicant: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION

Inventor： Alejandro VILLAGRA ,  Satish NOONEPALLE ,  Maria del Mar Gracia HERNANDEZ

IPC: A61K39/00 ,  C12N5/0786 ,  A61K35/15 ,  A61K45/06

CPC classification number: A61K39/4614 ,  C12N5/0645 ,  A61K39/464495 ,  A61K39/464491 ,  A61K39/464486 ,  A61K39/464488 ,  A61K39/46449 ,  A61K39/464482 ,  A61K39/464481 ,  A61K39/46447 ,  A61K39/464456 ,  A61K39/464451 ,  A61K39/4644 ,  A61K35/15 ,  A61K45/06 ,  C12N2501/2304 ,  C12N2501/2313 ,  A61K2039/5154

Abstract: The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods of making STAT-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of STAT-activated macrophages.

公开(公告)号：US20230210982A1

公开(公告)日：2023-07-06

申请号：US18061045

申请日：2022-12-02

Applicant: AIVITA BIOMEDICAL, INC

Inventor： Gabriel NISTOR ,  Hans KIERSTEAD ,  Robert O. DILLMAN

IPC: A61K39/215 ,  C12N5/0784

CPC classification number: A61K39/215 ,  C12N5/0639 ,  C12N2501/2304 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/24 ,  A61K2039/5154

Abstract: Disclosed herein is a kit to produce a personalized vaccine based on autologous dendritic cells. The kit contains all the materials, reagents and information necessary to produce a dose of live dendritic cell vaccine against a pathogen organism, part of a pathogen organism, a toxin, a venom, a structure obtained by recombinant method or chemical synthesis.